

Disclosures

Personal Commercial (17)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
argenx	Research/Research Grants ‡ Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS (POTS)	Significant (>= \$5,000)	Other
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
CSL Behring	Consultant Fees/Honoraria	Modest (< \$5,000)	Arrhythmias and Clinical EP
Dexcom	Research/Research Grants	Modest (< \$5,000)	Prevention
Edwards	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Eli Lilly and Company	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Epirium Bio	Stock	Modest (< \$5,000)	Other
Esperion	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
jazz pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Medtronic	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Merck & Co., Inc.	Research/Research Grants	Modest (< \$5,000)	General Cardiology
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Novartis Corporation	Research/Research Grants ‡ Victorian-2 Prevent	Significant (>= \$5,000)	General Cardiology
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Sanofi-Aventis	Consultant Fees/Honoraria	Modest (< \$5,000)	Arrhythmias and Clinical EP

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 12/16/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.